The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.
Bio-Techne Corp. (TECH)
Common Stock · Currency in USD · XNAS
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Company Info
SIC2836
Composite FIGIBBG000C15114
CIK0000842023
IPOMay 8, 1989
Sectorbiological products, (no diagnostic substances)
Highlights
Market Cap$8.31B
EPS$0.96
P/E Ratio54.67
Revenue$1.16B
Gross Profit$765.11M
Net Income$152.04M
Employees3,100
WSO156,453,292
Phone612-379-8854
Websitehttps://www.bio-techne.com
Related Tickers
A
Agilent Technologies Inc.
$115.48 0.00%
RVTY
Revvity, Inc.
$88.94 0.00%
TMO
Thermo Fisher Scientific, Inc.
$489.90 0.00%
MTD
Mettler-Toledo International
$1.26K 0.00%
IQV
IQVIA Holdings Inc.
$173.26 0.00%
BRKR
Bruker Corporation
$36.90 0.00%
DHR
Danaher Corporation
$191.12 0.00%
WAT
Waters Corp
$304.24 0.00%
BIO
Bio-Rad Laboratories, Inc.Class A
$279.99 0.00%
CRL
Charles River Laboratories International, Inc.
$173.89 0.00%
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Bio-Techne Corp., comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Bio-Techne Corp. (TECH) has returned -9.66% so far this year and 5.10% over the past 12 months. Looking at the last ten years, TECH has achieved an annualized return of 8.35%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
TECH
1M-6.61%
6M-15.60%
YTD-9.66%
1Y5.10%
5Y-12.19%
10Y8.35%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Bio-Techne Corp. (TECH) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.98% | -7.25% | -9.86% | 1.61% | ||||||||
| 2025 | 1.10% | -14.37% | -5.40% | -12.72% | -3.34% | 7.46% | 7.06% | 1.52% | 2.70% | 12.60% | 4.20% | -7.79% |
| 2024 | -7.93% | 9.64% | -4.21% | -10.66% | 9.43% | -8.01% | 13.67% | -9.68% | 8.78% | -7.73% | 1.70% | -4.00% |
| 2023 | -5.01% | -9.10% | 2.64% | 8.36% | 2.19% | -0.34% | 2.77% | -5.71% | -13.59% | -19.54% | 14.51% | 23.22% |
| 2022 | -27.14% | 2.89% | 3.21% | -13.18% | -2.03% | -6.14% | 11.15% | -13.04% | -13.51% | 3.57% | 19.00% | -2.62% |
| 2021 | 2.61% | 9.54% | 3.52% | 11.02% | -4.18% | 7.65% | 7.32% | 2.70% | -3.09% | 7.86% | -10.09% | 9.20% |
| 2020 | -4.80% | -10.45% | -0.31% | 21.12% | 29.51% | 0.08% | 4.39% | -8.26% | -3.91% | 1.95% | 18.85% | 3.79% |
| 2019 | 22.16% | 11.42% | 2.40% | 2.08% | -2.80% | 6.17% | -0.60% | -9.45% | 2.74% | 5.87% | 4.04% | 0.18% |
| 2018 | 8.15% | 0.83% | 6.42% | 0.28% | -0.38% | -2.36% | 8.85% | 18.65% | 6.55% | -17.97% | -2.82% | -11.58% |
| 2017 | -1.46% | 3.97% | -5.27% | 5.10% | 4.25% | 4.59% | -1.88% | 6.38% | -2.51% | 8.24% | 1.71% | -3.88% |
| 2016 | -0.77% | 18.01% | 3.17% | -0.27% | -6.68% | 4.13% | -4.92% | 0.93% | -3.05% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Bio-Techne Corp. (TECH) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of TECH compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Bio-Techne Corp. volatility is 2.41%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 2.56B | 2.70B | 2.64B | 2.29B | 2.26B | 2.03B | 1.88B | 1.59B | 1.56B | 1.13B | 1.06B | 862.49M | 778.10M | 719.32M | 617.67M |
| Equity Attributable To Parent (USD) | 1.92B | 2.07B | 1.97B | 1.70B | 1.56B | 1.38B | 1.17B | 1.08B | 949.63M | 879.28M | 846.94M | 795.27M | 737.54M | 674.44M | 586.12M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | -759.00K | 8.26M | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 1.92B | 2.07B | 1.97B | 1.70B | 1.57B | 1.38B | 1.17B | 1.08B | 949.63M | 879.28M | 846.94M | 795.27M | 737.54M | 674.44M | 586.12M |
| Noncurrent Liabilities (USD) | 463.21M | 475.64M | 543.67M | 417.78M | 539.44M | 539.73M | 616.84M | 434.63M | 473.07M | 196.15M | 176.66M | 40.84M | 8.47M | 9.13M | 13.36M |
| Other Current Liabilities (USD) | 84.75M | 71.59M | 66.08M | 80.20M | 71.61M | 52.49M | 57.14M | 37.35M | 92.06M | 18.63M | 15.98M | 10.58M | 21.82M | 24.76M | 8.20M |
| Wages (USD) | 65.79M | 49.82M | 36.75M | 61.95M | 51.29M | 31.09M | 28.64M | 23.71M | 26.60M | 14.87M | 10.34M | 6.16M | 4.03M | 4.70M | 4.78M |
| Accounts Payable (USD) | 25.31M | 37.97M | 25.68M | 33.87M | 29.38M | 23.09M | 16.21M | 18.45M | 16.86M | 20.65M | 13.44M | 9.65M | 6.24M | 6.29M | 5.21M |
| Current Liabilities (USD) | 175.85M | 159.38M | 128.51M | 176.02M | 152.28M | 106.67M | 101.99M | 79.51M | 135.52M | 54.15M | 39.77M | 26.39M | 32.08M | 35.75M | 18.19M |
| Liabilities (USD) | 639.06M | 635.02M | 672.18M | 593.79M | 691.72M | 646.40M | 718.82M | 514.14M | 608.59M | 250.30M | 216.43M | 67.23M | 40.56M | 44.88M | 31.55M |
| Other Non-current Assets (USD) | 1.34B | 1.33B | 1.26B | 934.49M | 928.48M | 813.30M | 738.34M | 603.16M | 623.03M | 432.80M | 685.33M | 275.96M | 259.83M | 279.03M | 291.86M |
| Intangible Assets (USD) | 365.60M | 507.08M | 534.65M | 531.52M | 615.97M | 516.55M | 579.43M | 446.33M | 452.04M | 310.52M | - | - | - | - | - |
| Fixed Assets (USD) | 245.72M | 251.15M | 226.20M | 223.24M | 207.91M | 176.83M | 154.04M | 145.35M | 135.12M | 132.36M | 129.75M | 117.12M | 108.76M | 93.79M | 95.40M |
| Noncurrent Assets (USD) | 1.95B | 2.09B | 2.02B | 1.69B | 1.75B | 1.51B | 1.47B | 1.19B | 1.21B | 875.69M | 815.08M | 393.08M | 368.58M | 372.82M | 387.25M |
| Other Current Assets (USD) | 418.85M | 437.69M | 449.84M | 464.43M | 393.86M | 417.77M | 321.56M | 312.72M | 287.87M | 196.79M | 198.71M | 427.98M | 373.11M | 306.73M | 184.47M |
| Prepaid Expenses (USD) | - | - | - | - | - | - | - | - | - | - | - | 2.59M | 1.53M | 1.50M | 1.04M |
| Inventory (USD) | 189.45M | 179.73M | 171.64M | 141.12M | 116.75M | 103.15M | 91.05M | 85.65M | 60.15M | 57.10M | 49.58M | 38.85M | 34.88M | 38.28M | 44.91M |
| Current Assets (USD) | 608.30M | 617.42M | 621.48M | 605.56M | 510.61M | 520.92M | 412.61M | 398.37M | 348.03M | 253.89M | 248.28M | 469.41M | 409.52M | 346.51M | 230.42M |
| Assets (USD) | 2.56B | 2.70B | 2.64B | 2.29B | 2.26B | 2.03B | 1.88B | 1.59B | 1.56B | 1.13B | 1.06B | 862.49M | 778.10M | 719.32M | 617.67M |
News and Insights
Bio-Techne Declares Dividendpositive
Bio-Techne Corporation (NASDAQ: TECH) announced a quarterly dividend of $0.08 per share for the quarter ended December 31, 2025, payable on February 27, 2026, to shareholders of record on February 16, 2026. The company generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulatory requirements and high manufacturing costs.
BIO-TECHNE DECLARES DIVIDENDpositive
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on November 28, 2025, to shareholders of record on November 17, 2025. The global life sciences company generated over $1.2 billion in net sales in fiscal 2025.
MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.
RBC Capital upgraded Bio-Techne to Outperform, raising price target from $61 to $73, citing potential for mid-single-digit revenue growth and attractive valuation after recent market selloff.
The global recombinant human hair keratin protein market is experiencing rapid growth, driven by increasing demand in biomedical and cosmetic applications, with North America leading and Asia-Pacific showing the fastest growth potential by 2034.
Bio-Techne reported Q4 fiscal 2025 earnings with modest revenue beat and non-GAAP EPS growth, but faced challenges including an $83.1 million impairment loss from divesting Exosome Diagnostics and margin pressures in its Diagnostics segment.
BIO-TECHNE DECLARES DIVIDENDneutral
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share, payable on August 29, 2025, to shareholders of record as of August 18, 2025. The company is a global life sciences organization that generated approximately $1.2 billion in net sales in fiscal 2025.
Bio-Techne announced a quarterly dividend of $0.08 per share and a new $500 million share repurchase program, replacing the previous program.